Altimmune said it expects to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in MASH. The company is also awaiting data from related alcohol-associated liver disease programs, leaving the outlook dependent on upcoming clinical readouts. The update is operationally meaningful but remains early-stage and largely event-driven.
Altimmune said it expects to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in MASH. The company is also awaiting data from related alcohol-associated liver disease programs, leaving the outlook dependent on upcoming clinical readouts. The update is operationally meaningful but remains early-stage and largely event-driven.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
